ATE380822T1 - Funf-helix protein - Google Patents

Funf-helix protein

Info

Publication number
ATE380822T1
ATE380822T1 AT00986475T AT00986475T ATE380822T1 AT E380822 T1 ATE380822 T1 AT E380822T1 AT 00986475 T AT00986475 T AT 00986475T AT 00986475 T AT00986475 T AT 00986475T AT E380822 T1 ATE380822 T1 AT E380822T1
Authority
AT
Austria
Prior art keywords
helix protein
helices
linkers
trimer
hiv
Prior art date
Application number
AT00986475T
Other languages
English (en)
Inventor
Michael J Root
Michael S Kay
David C Chan
Peter S Kim
Original Assignee
Whitehead Biomedical Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Whitehead Biomedical Inst filed Critical Whitehead Biomedical Inst
Application granted granted Critical
Publication of ATE380822T1 publication Critical patent/ATE380822T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00986475T 1999-12-16 2000-12-15 Funf-helix protein ATE380822T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17104299P 1999-12-16 1999-12-16
US23457200P 2000-09-22 2000-09-22

Publications (1)

Publication Number Publication Date
ATE380822T1 true ATE380822T1 (de) 2007-12-15

Family

ID=26866680

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00986475T ATE380822T1 (de) 1999-12-16 2000-12-15 Funf-helix protein

Country Status (8)

Country Link
US (3) US7053179B2 (de)
EP (1) EP1237912B1 (de)
JP (1) JP4925540B2 (de)
AT (1) ATE380822T1 (de)
CA (1) CA2395291C (de)
DE (1) DE60037450T2 (de)
ES (1) ES2296665T3 (de)
WO (1) WO2001044286A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150088A (en) * 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6747126B1 (en) * 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) * 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
CA2359892A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
US20030082525A1 (en) * 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
US6861253B2 (en) 2001-01-05 2005-03-01 Aventis Pasteur S.A. Polypeptide inducing antibodies neutralizing HIV
FR2819256B1 (fr) * 2001-01-05 2004-04-30 Aventis Pasteur Polypeptide induisant des anticorps neutralisant le vih
DK1479691T3 (da) 2001-05-31 2007-03-12 John Erickson Langvarigt aktive fuionspeptidinhibitorer for HIV infektion
CA2450548C (en) 2001-06-15 2012-05-01 F. Hoffmann-La Roche Ag Method for the recombinant production of peptidic antiviral fusion inhibitors, and acetylation of gb41 fragments
US20030125515A1 (en) * 2001-07-11 2003-07-03 Genfa Zhou End-locked five-helix protein
WO2003027255A2 (en) * 2001-09-27 2003-04-03 Tibotec Pharmaceuticals Ltd. Anti-fusion assay
PT1442124E (pt) * 2001-10-05 2007-02-28 Sanofi Pasteur Antigénio polipeptídico formando uma estrutura que mimetiza o estado intermédio da gp41
US20030219451A1 (en) * 2001-10-29 2003-11-27 Whitehead Institute For Biomedical Research Stable helical C peptides and uses therefor
FR2832715A1 (fr) * 2001-11-29 2003-05-30 Hippocampe Polypeptides inhibiteurs de l'infectivite des virus de l'immunodeficience humaine
US20060241027A1 (en) * 2002-02-07 2006-10-26 Hans-Peter Hauser Hiv inhibiting proteins
US7056519B2 (en) 2002-05-17 2006-06-06 Aventis Pasteur S.A. Methods for inducing HIV-neutralizing antibodies
US20040076637A1 (en) * 2002-09-27 2004-04-22 Delmedico Mary Kay HIV-derived HR1 peptides modified to form stable trimers, and their use in therapy to inhibit transmission of human immunodeficiency virus
CA2443365C (en) * 2002-11-19 2010-01-12 F. Hoffmann-La Roche Ag Methods for the recombinant production of antifusogenic peptides
AU2003265420A1 (en) * 2003-08-14 2005-03-10 The Government Of The United States Of America, As Represented By The Department Of Health And Human Services Polypeptide multimers having antiviral activity
CA2565658A1 (en) * 2004-05-06 2005-11-17 Conjuchem Biotechnologies Inc. Compounds for specific viral target
ATE516048T1 (de) * 2004-06-01 2011-07-15 Merck Sharp & Dohme Mit hiv gp41 in wechselwirkung stehende menschliche antikörper
EP2354153A3 (de) * 2004-06-01 2012-05-30 Merck Sharp & Dohme Corp. Stabiles Peptidmimetikum des HIV-gp41-Fusionszwischenprodukts
US7491489B2 (en) * 2004-11-22 2009-02-17 The University Of Hong Knog Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereof
EP2314320A2 (de) * 2005-04-05 2011-04-27 Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. Verfahren zur Abschirmung von funktionalen Stellen oder Epitopen von Proteinen
CN101088557A (zh) 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20100029568A1 (en) * 2007-03-12 2010-02-04 Thomas Jefferson University Tighter-binding c-peptide inhibitors of hiv-1 entry
US9217011B2 (en) * 2007-09-07 2015-12-22 Complix Nv Non-natural proteinaceous scaffold made of three non-covalently associated peptides
GB0720503D0 (en) * 2007-10-22 2007-11-28 Angeletti P Ist Richerche Bio New compound
GB2471692A (en) 2009-07-08 2011-01-12 Complix Nv HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats
US9050063B2 (en) * 2012-03-30 2015-06-09 Sandance Technology Llc Systems and methods for determining suitability of a mechanical implant for a medical procedure
CN106946994B (zh) * 2017-03-09 2019-11-26 中国医学科学院病原生物学研究所 一种抑制丙型肝炎病毒感染的蛋白及其应用
CN110551179B (zh) * 2018-05-31 2022-03-15 中国科学院微生物研究所 一种经修饰的抗hiv多肽及其制备方法和用途
EP4519285A1 (de) 2022-05-03 2025-03-12 F. Hoffmann-La Roche AG Hiv gp41 varianten für immundiagnostische tests

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5444044A (en) 1992-03-26 1995-08-22 New York Blood Center Synthetic polypeptides as inhibitors of HIV-1
AU688733B2 (en) 1992-07-20 1998-03-19 Duke University Compounds which inhibit HIV replication
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US5780221A (en) 1995-05-03 1998-07-14 Whitehead Institute For Biomedical Research Identification of enantiomeric ligands
US6475491B1 (en) * 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
JP3903503B2 (ja) 1996-11-18 2007-04-11 住友電気工業株式会社 可溶性ポリペプチド
AU6649698A (en) * 1997-01-28 1998-08-18 Regents Of The University Of California, The Peptide probes to coil proteins and methods for making the same
US6818740B1 (en) 1997-04-17 2004-11-16 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6841657B2 (en) 1997-04-17 2005-01-11 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
US6150088A (en) 1997-04-17 2000-11-21 Whitehead Institute For Biomedical Research Core structure of gp41 from the HIV envelope glycoprotein
US6090911A (en) 1997-10-22 2000-07-18 University Of Massachusetts Reversible hydrogels
US6656906B1 (en) 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
JP5101764B2 (ja) 1998-07-30 2012-12-19 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ膜融合のインヒビター
US6747126B1 (en) 1998-07-30 2004-06-08 Whitehead Institute For Biomedical Research Peptide inhibitors of HIV entry
US7960504B2 (en) 1998-07-30 2011-06-14 Whitehead Institute For Biomedical Research Inhibitors of HIV membrane fusion
CA2359892A1 (en) * 1999-01-08 2000-07-13 Panacos Pharmaceuticals, Inc. Methods of eliciting broadly neutralizing antibodies targeting hiv-1 gp41
US20030082525A1 (en) 1999-12-16 2003-05-01 Whitehead Institute For Biomedical Research Five-Helix protein
CA2395291C (en) 1999-12-16 2012-09-11 Whitehead Institute For Biomedical Research Five-helix protein
JP5180422B2 (ja) 2000-09-22 2013-04-10 ホワイトヘッド インスチチュート フォアー バイオメディカル リサーチ Ｈｉｖ浸入のペプチドインヒビター

Also Published As

Publication number Publication date
WO2001044286A3 (en) 2002-01-24
JP4925540B2 (ja) 2012-04-25
DE60037450T2 (de) 2008-12-04
WO2001044286A2 (en) 2001-06-21
US7053179B2 (en) 2006-05-30
US7504224B2 (en) 2009-03-17
US8058012B2 (en) 2011-11-15
EP1237912B1 (de) 2007-12-12
US20100196397A1 (en) 2010-08-05
CA2395291A1 (en) 2001-06-21
JP2003517006A (ja) 2003-05-20
ES2296665T3 (es) 2008-05-01
US20010047080A1 (en) 2001-11-29
CA2395291C (en) 2012-09-11
US20060014139A1 (en) 2006-01-19
EP1237912A2 (de) 2002-09-11
DE60037450D1 (de) 2008-01-24

Similar Documents

Publication Publication Date Title
DE60037450D1 (de) Funf-helix protein
DE60144145D1 (de) Subtilisin-variante
DK1149905T3 (da) Fremgangsmåder og præparat til polypeptidteknologi
EP0675904A4 (de) Humane neutralisierende monoklonale antikörper gegen den die immunschwäche auslösenden virus aus mensch.
ATE270557T1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
NO20020348L (no) Peptid acceptor ligeringsmetoder
EP0695171A1 (de) Gonadotropin enthaltende gefriergetrocknete troepfen
EE200300408A (et) Aktiivsete valkude saagise suurendamine
DK1159298T3 (da) HIV-peptider, antigener og vaccinekompositioner
EP1149115A4 (de) Verfahren zum hervorrufen von breit wirksamen, neutralisierenden antikörpern, die gegen gp41 von hiv-1 gerichtet sind.
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
NO20030495L (no) Peptider som presenteres av celler
IS6678A (is) Hvarfefni og prófanir fyrir ß-sekretasavirkni
IT1299583B1 (it) Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
TR200000697T2 (tr) İkame edilmiş 1,2,3,4,5,6-Heksahidro-2,6-Metano-3-Benzazosin-10-OL'ler, üretim yöntemleri ve farmasötik preparat olarak kullanımları.
PT1107793E (pt) Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados
FR2819809B1 (fr) Peptides presentant un affinite pour la proteine virale gp120, et utilisation de ces peptides
DE60044303D1 (de) Nicht-immunsuppresives hiv tat-protein
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DE69736779D1 (de) Zusammensetzungen von rekombinanten papillomavirus vakzinen
DK0541753T3 (da) Hidtil ukendt hybrid, opløselig og ikke-spaltelig gp160-variant
AU8405798A (en) A swine hepatitis e virus and uses thereof
IT1312569B1 (it) Uso dell'enzima gssg reduttasi per il trattamento terapeutico e laprofilassi di pazienti infettati da hiv.
AU2190288A (en) Vector for the expression of proteins of the HIV-2 virus, one of the casual agents of AIDS, cell culture infected or transformed by this vector, proteins obtained, vaccine and antibodies obtained

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties